UnitedHealth Group (NYSE: UNH) is scheduled to report its Q2 2024 results on Tuesday, October 15. We expect UnitedHealth to post revenue of $99 billion and earnings of $6.95 on a per-share and adjusted basis, slightly below the street expectations.
Evaluate the expected performance of UnitedHealth (UNH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
UNH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
CVS Health and UnitedHealth Group have asked U.S. Federal Trade Commission chair Lina Khan and commissioners Rebecca Kelly Slaughter and Alvaro Bedoya to disqualify themselves from an FTC lawsuit that has accused the companies of unlawfully inflating insulin prices.
In the most recent trading session, UnitedHealth Group (UNH) closed at $583.56, indicating a -1.29% shift from the previous trading day.
UnitedHealth (UNH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
UnitedHealth Group (UNH) concluded the recent trading session at $584.68, signifying a +0.49% move from its prior day's close.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.
The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.
With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.